BioTuesdays

Tag - ANVS

Annovis Logo
Markets

Maxim ups Annovis Bio PT to $45 from $12

Maxim Group raised its price target for Annovis Bio (NYSE American: ANVS) to $45 from $12, citing upcoming Phase 2a data evaluating ANVS401 in Alzheimer’s disease (AD) and Parkinson’s disease (PD) patients. The stock...

May 13, 2021
Annovis Logo
Markets

Maxim starts Annovis Bio at buy; PT $12

Maxim Group launched coverage of Annovis Bio (NYSE American:ANVS) with a “buy” rating and $12 price target. The stock closed at $5 on June 17. Annovis’ ANVS401 is a disease-modifying agent for chronic neurodegenerative...

June 18, 2020